Danielle Antalffy
Stock Analyst at UBS
(3.64)
# 715
Out of 4,843 analysts
164
Total ratings
48.98%
Success rate
6.18%
Average return
Main Sectors:
Stocks Rated by Danielle Antalffy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMCI Treace Medical Concepts | Maintains: Neutral | $10 → $8.6 | $5.76 | +49.31% | 6 | May 9, 2025 | |
| ATRC AtriCure | Maintains: Buy | $60 → $58 | $34.57 | +67.78% | 13 | Apr 30, 2025 | |
| INMD InMode | Maintains: Neutral | $19 → $16 | $14.66 | +10.85% | 4 | Apr 29, 2025 | |
| RXST RxSight | Downgrades: Neutral | $45 → $16 | $15.29 | +4.64% | 3 | Apr 9, 2025 | |
| MDT Medtronic | Maintains: Neutral | $85 → $95 | $82.98 | +14.49% | 8 | Feb 19, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $105 → $130 | $105.26 | +23.50% | 12 | Feb 7, 2025 | |
| SGHT Sight Sciences | Maintains: Buy | $5.5 → $5 | $3.70 | +35.14% | 2 | Jan 27, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $146 → $148 | $133.58 | +10.80% | 12 | Jan 23, 2025 | |
| GKOS Glaukos | Initiates: Buy | $182 | $94.29 | +93.02% | 1 | Dec 6, 2024 | |
| SYK Stryker | Maintains: Neutral | $366 → $370 | $382.64 | -3.30% | 6 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $75 | $78.22 | -4.12% | 12 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $112 → $107 | $92.17 | +16.09% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $163 → $95 | $85.80 | +10.72% | 8 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $31.30 | +139.62% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $180 | $155.21 | +15.97% | 4 | Dec 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $405 → $322 | $138.20 | +133.00% | 5 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $2.25 | $2.40 | -6.25% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $43 | $30.50 | +40.98% | 5 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $278 | $552.34 | -49.67% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $45 | $19.82 | +127.04% | 14 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $280 | $325.03 | -13.85% | 12 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $975 → $825 | $17.75 | +4,547.89% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $10.89 | +28.56% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $100 | $75.56 | +32.35% | 2 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $12 | $13.22 | -9.23% | 3 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $30 | $58.00 | -48.28% | 3 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $41.30 | +8.97% | 4 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $270 → $275 | $172.59 | +59.34% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $2.74 | +629.93% | 3 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $72 → $42 | $6.47 | +549.15% | 7 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.52 | +473.07% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $0.84 | +1,685.71% | 1 | Sep 1, 2020 |
Treace Medical Concepts
May 9, 2025
Maintains: Neutral
Price Target: $10 → $8.6
Current: $5.76
Upside: +49.31%
AtriCure
Apr 30, 2025
Maintains: Buy
Price Target: $60 → $58
Current: $34.57
Upside: +67.78%
InMode
Apr 29, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $14.66
Upside: +10.85%
RxSight
Apr 9, 2025
Downgrades: Neutral
Price Target: $45 → $16
Current: $15.29
Upside: +4.64%
Medtronic
Feb 19, 2025
Maintains: Neutral
Price Target: $85 → $95
Current: $82.98
Upside: +14.49%
Boston Scientific
Feb 7, 2025
Maintains: Buy
Price Target: $105 → $130
Current: $105.26
Upside: +23.50%
Sight Sciences
Jan 27, 2025
Maintains: Buy
Price Target: $5.5 → $5
Current: $3.70
Upside: +35.14%
Abbott Laboratories
Jan 23, 2025
Maintains: Buy
Price Target: $146 → $148
Current: $133.58
Upside: +10.80%
Glaukos
Dec 6, 2024
Initiates: Buy
Price Target: $182
Current: $94.29
Upside: +93.02%
Stryker
Oct 30, 2024
Maintains: Neutral
Price Target: $366 → $370
Current: $382.64
Upside: -3.30%
Sep 10, 2024
Maintains: Neutral
Price Target: $90 → $75
Current: $78.22
Upside: -4.12%
Aug 8, 2024
Maintains: Sell
Price Target: $112 → $107
Current: $92.17
Upside: +16.09%
Jul 26, 2024
Maintains: Buy
Price Target: $163 → $95
Current: $85.80
Upside: +10.72%
Jan 22, 2024
Initiates: Buy
Price Target: $75
Current: $31.30
Upside: +139.62%
Dec 1, 2023
Upgrades: Buy
Price Target: $180
Current: $155.21
Upside: +15.97%
Sep 6, 2023
Maintains: Buy
Price Target: $405 → $322
Current: $138.20
Upside: +133.00%
Mar 29, 2023
Initiates: Neutral
Price Target: $2.25
Current: $2.40
Upside: -6.25%
Mar 29, 2023
Initiates: Neutral
Price Target: $43
Current: $30.50
Upside: +40.98%
Mar 29, 2023
Initiates: Neutral
Price Target: $278
Current: $552.34
Upside: -49.67%
Mar 29, 2023
Initiates: Neutral
Price Target: $45
Current: $19.82
Upside: +127.04%
May 6, 2022
Maintains: Outperform
Price Target: $300 → $280
Current: $325.03
Upside: -13.85%
May 5, 2022
Maintains: Outperform
Price Target: $975 → $825
Current: $17.75
Upside: +4,547.89%
May 5, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $10.89
Upside: +28.56%
May 2, 2022
Maintains: Outperform
Price Target: $75 → $100
Current: $75.56
Upside: +32.35%
Mar 11, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $13.22
Upside: -9.23%
Mar 9, 2022
Maintains: Outperform
Price Target: $25 → $30
Current: $58.00
Upside: -48.28%
Feb 25, 2022
Maintains: Outperform
Price Target: $40 → $45
Current: $41.30
Upside: +8.97%
Feb 4, 2022
Maintains: Market Perform
Price Target: $270 → $275
Current: $172.59
Upside: +59.34%
Nov 10, 2021
Maintains: Outperform
Price Target: $26 → $20
Current: $2.74
Upside: +629.93%
Nov 5, 2021
Maintains: Market Perform
Price Target: $72 → $42
Current: $6.47
Upside: +549.15%
Apr 1, 2021
Downgrades: Market Perform
Price Target: $3
Current: $0.52
Upside: +473.07%
Sep 1, 2020
Initiates: Outperform
Price Target: $15
Current: $0.84
Upside: +1,685.71%